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STUDY QUESTION: Does endometrial scratching in women with one failed IVF/ICSI treatment affect the chance of a live birth of the
subsequent fresh IVF/ICSI cycle?
SUMMARY ANSWER: In this study, 4.6% more live births were observed in the scratch group, with a likely certainty range between
0.7% and þ9.9%.
WHAT IS KNOWN ALREADY: Since the first suggestion that endometrial scratching might improve embryo implantation during
IVF/ICSI, many clinical trials have been conducted. However, due to limitations in sample size and study quality, it remains unclear whether
endometrial scratching improves IVF/ICSI outcomes.
STUDY DESIGN, SIZE, DURATION: The SCRaTCH trial was a non-blinded randomised controlled trial in women with one
unsuccessful IVF/ICSI cycle and assessed whether a single endometrial scratch using an endometrial biopsy catheter would lead to a higher
live birth rate after the subsequent IVF/ICSI treatment compared to no scratch. The study took place in 8 academic and 24 general
hospitals. Participants were randomised between January 2016 and July 2018 by a web-based randomisation programme. Secondary
outcomes included cumulative 12-month ongoing pregnancy leading to live birth rate.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with one previous failed IVF/ICSI treatment and planning a second
fresh IVF/ICSI treatment were eligible. In total, 933 participants out of 1065 eligibles were included (participation rate 88%).
MAIN RESULTS AND THE ROLE OF CHANCE: After the fresh transfer, 4.6% more live births were observed in the scratch
compared to control group (110/465 versus 88/461, respectively, risk ratio (RR) 1.24 [95% CI 0.96–1.59]). These data are consistent
with a true difference of between 0.7% and þ9.9% (95% CI), indicating that while the largest proportion of the 95% CI is positive,
scratching could have no or even a small negative effect. Biochemical pregnancy loss and miscarriage rate did not differ between the two
groups: in the scratch group 27/153 biochemical pregnancy losses and 14/126 miscarriages occurred, while this was 19/130 and 17/111
for the control group (RR 1.21 (95% CI 0.71–2.07) and RR 0.73 (95% CI 0.38–1.40), respectively). After 12 months of follow-up, 5.1%
more live births were observed in the scratch group (202/467 versus 178/466), of which the true difference most likely lies between
1.2% and þ11.4% (95% CI).
LIMITATIONS, REASONS FOR CAUTION: This study was not blinded. Knowledge of allocation may have been an incentive for
participants allocated to the scratch group to continue treatment in situations where they may otherwise have cancelled or stopped.
In addition, this study was powered to detect a difference in live birth rate of 9%.
WIDER IMPLICATIONS OF THE FINDINGS: The results of this study are an incentive for further assessment of the efficacy and
clinical implications of endometrial scratching. If a true effect exists, it may be smaller than previously anticipated or may be limited to
specific groups of women undergoing IVF/ICSI. Studying this will require larger sample sizes, which will be provided by the ongoing
international individual participant data-analysis (PROSPERO CRD42017079120). At present, endometrial scratching should not be
performed outside of clinical trials.
STUDY FUNDING/COMPETING INTEREST(S): This study was funded by ZonMW, the Dutch organisation for funding healthcare
research. J.S.E. Laven reports grants and personal fees from AnshLabs (Webster, Tx, USA), Ferring (Hoofddorp, The Netherlands) and
Ministry of Health (CIBG, The Hague, The Netherlands) outside the submitted work. A.E.P. Cantineau reports ‘other’ from Ferring BV,
personal fees from Up to date Hyperthecosis, ‘other’ from Theramex BV, outside the submitted work. E.R. Groenewoud reports grants
from Titus Health Care during the conduct of the study. A.M. van Heusden reports personal fees from Merck Serono, personal fees from
Ferring, personal fees from Goodlife, outside the submitted work. F.J.M. Broekmans reports personal fees as Member of the external advi-
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Introduction
Each year 2.4 million IVF/ICSI cycles are carried out globally (De
Geyter et al., 2018; Fauser, 2019). Despite advances in techniques,
pregnancy rates still remain maximally 35% per embryo transfer and
embryo implantation seems to be the rate-limiting step in the success
of IVF/ICSI treatment (De Geyter et al., 2018). Endometrial scratching
has been suggested as a promising add-on treatment to improve IVF/
ICSI pregnancy rates (Barash et al., 2003; Nastri et al., 2015), even
though its effectiveness (Panagiotopoulou et al., 2015; Santamaria































































































et al., 2016), and the potential underlying biological mechanisms
(Li and Hao, 2009; Gnainsky et al., 2015) have not been proven.
Nevertheless, since the publication of the first randomised controlled
trials (RCTs) in 2010, endometrial scratching has been widely imple-
mented in daily practice (Lensen et al., 2016, 2019b; Farquhar, 2019;
Mol and Barnhart, 2019).
At present, it is still unclear if endometrial scratching improves
the chance of a live birth and, if so, which population benefits most
(Yeung et al., 2014; Nastri et al., 2015; Vitagliano et al., 2018;
Lensen et al., 2019a; van Hoogenhuijze et al., 2019). Most studies
that reported a positive effect on pregnancy chances were associ-
ated with a high risk of bias (Nastri et al., 2015; Vitagliano et al.,
2018; van Hoogenhuijze et al., 2019) and often only outcomes such
as clinical- or ongoing pregnancy were reported, while a live birth is
considered as the most important outcome (Legro and Wu, 2014).
The only large RCT to date did not standardise the method of en-
dometrial scratching and had a follow-up duration of one embryo
transfer (Lensen et al., 2019a). Also, the participation rate was only
around 50% of eligible women, which may have impacted the gener-
alisability of the findings.
With the SCRaTCH trial, our aim was to study whether endome-
trial scratching using an endometrial biopsy catheter improves live birth
rates both in the short and long term in a large, relatively homoge-
neous population, with at least one previous failed embryo transfer.
This led to our research question ‘does a single mid-luteal endometrial
scratch in women with one failed IVF/ICSI treatment affect the chance
of a live birth of the subsequent fresh IVF/ICSI cycle?’.
Materials and methods
Study design and participants
This trial was a multicentre, randomised controlled, non-blinded trial
executed in 8 academic and 24 general hospitals in the Netherlands.
The trial was coordinated by the University Medical Centre Utrecht
and was performed within the Dutch Consortium for Healthcare
Evaluation and Research in Obstetrics and Gynaecology (NVOG
Consortium 2.0). Eligible women were recruited and counselled by
staff of the participating hospitals. The study protocol was published
previously (van Hoogenhuijze et al., 2017b).
In short, women were eligible if they had undergone one full IVF/
ICSI cycle with at least one embryo transfer without achieving a clinical
pregnancy and were planning a new fresh IVF/ICSI cycle. Inclusion cri-
teria were regular indication for IVF/ICSI, age 18–44 years, primary or
secondary infertility and a normal transvaginal ultrasound. Exclusion cri-
teria were endometriosis grade III/IV, untreated uni- or bilateral
hydrosalpinx, previous endometrial scratching, untreated endocrine ab-
normalities, intermenstrual blood loss, previous Caesarean section
with niche-formation and intracavitary fluid visible on ultrasound, in-
creased risk of intra-abdominal infection, oocyte donation cycles or
pre-implantation genetic testing.
Ethics approval was obtained from the institutional review board of
the University Medical Centre Utrecht (METC 10-272). Approval was
obtained from the board of directors of each participating centre. All
women gave written informed consent.
Randomisation
Participants were randomised after the last failed embryo transfer and
prior to the start of medication for the second fresh IVF/ICSI treat-
ment by a staff member of the participating centre. Participants were
randomised 1:1 to the intervention or control group by a centrally lo-
cated, non-centre-stratified, web-based randomisation programme
(ALEA Clinical B.V.) using randomly permuted blocks, with block size
varying randomly between two and four.
Study procedure
Participants allocated to the intervention group received a single endo-
metrial scratch in the menstrual cycle prior to the start of stimulation
for IVF/ICSI. The scratch was performed either in the mid-luteal phase
of a natural cycle or in a cycle with hormonal contraceptives. Timing
of the scratch was determined by the LH surge through urine ovula-
tion tests (LHþ 5–8 days), the cycle day (5–10 days before the
expected next menstruation), or the planned last day of contraceptive
use (5–10 days before the expected withdrawal bleeding).
The scratch was performed by a maximum of two or three physi-
cians per participating centre, who followed a strict protocol as de-
scribed previously (van Hoogenhuijze et al., 2017b). Endometrial
scratching was performed by suction, using an endometrial biopsy
catheter. Directly afterwards, participants indicated the maximum pain
level during the scratch on a visual analogue score (VAS). One week
later, participants who had undergone a scratch procedure were asked
by phone whether they had experienced abdominal pain, vaginal
bleeding other than the menstruation, or fever.
Participants allocated to the control group did not undergo endo-
metrial scratching or a sham intervention.
Follow-up
Follow-up ended at 12 months after randomisation or, if an ongoing
pregnancy was achieved within that period, after giving birth. If a par-
ticipant became pregnant, ultrasonic evaluation was performed at 6–7
and 10–12 weeks’ gestational age. Follow-up information was retrieved
from the electronic patient file or via a questionnaire sent to the par-
ticipant. If questionnaires were not returned, information was obtained
by telephone contact with the participant, general practitioner or the
clinic where the participant continued treatment. If obtaining follow-up
information was unsuccessful, participants were marked as lost to fol-
low-up.
Outcomes
The primary outcome was live birth after a fresh transfer from the sec-
ond IVF/ICSI treatment (i.e. the first cycle after randomisation).
Secondary outcomes were implantation rate after the second fresh
IVF/ICSI treatment (only calculated for women with an embryo trans-
fer); biochemical pregnancy loss and miscarriage rate after the second
fresh IVF/ICSI treatment; cumulative live birth after the full second
IVF/ICSI treatment (i.e. including all fresh and frozen embryo trans-
fers); cumulative biochemical-, clinical-, ongoing pregnancy rate, ongo-
ing pregnancy leading to live birth rate and multiple pregnancy rate
within 12 months after randomisation; and time to biochemical preg-
nancy leading to live birth. Clinical pregnancy was defined as an intra-
uterine gestational sac visible on ultrasound at 6–7 weeks’ gestational































































































age; ongoing pregnancy as a positive heartbeat on ultrasound at 10
weeks’ gestational age; live birth as the delivery of at least one live foe-
tus after 24 weeks of gestation; and multiple pregnancy as the birth of
multiple live foetuses after 24 weeks of gestation.
As the live birth outcomes were defined as ‘ongoing pregnancy lead-
ing to live birth’, this implied that the ongoing pregnancy status should
be reached within 12 months after randomisation. In turn, this implies
that a biochemical pregnancy (gestational age 4 weeks) should be
reached within 323 days (10 months and 2 weeks) after randomisa-
tion. Thus, these criteria were used for all pregnancy outcomes mean-
ing that in case of a biochemical pregnancy loss, the biochemical
pregnancy should have occurred within 323 days after randomisation.
Statistical analysis
The sample size was calculated based on an estimated increase in the
primary outcome from 30% to 39%, an 80% power and a two-tailed
alpha of 5%. Taking a drop-out rate of 3% into account, 450 partici-
pants were needed per arm.
Pseudo-anonymised data were collected using a web-based registra-
tion system. Database cleaning consisted of internal consistency checks
and identifying entries outside the expected ranges.
A statistical analysis plan was drafted, signed and dated before
start of the analyses. The primary analysis was performed on an
intention-to-treat (ITT) basis. Furthermore, an as-treated (AT)
analysis and an as-treated analysis only including participants who
had a fresh embryo transfer (ATþET) were performed for the
primary outcome only. For the ITT and AT analysis, spontaneous
pregnancies occurring within 60 days after randomisation and preg-
nancies resulting from escape IUI were included in the analysis. All
cumulative outcomes were reported per participant, meaning that in
case of several (unsuccessful) pregnancies, only the last pregnancy
was reported. Participants who were lost to follow-up/withdrew
consent prior to the start of the second fresh IVF/ICSI treatment
were excluded from the analyses for the primary outcome and the
secondary outcome of the full second IVF/ICSI cycle, but they were
included in the conservative cumulative 12-month analyses (in which
they were regarded as no live birth).
All pregnancy outcomes were calculated by 2  2 contingency
tables and expressed as risk ratios (RR) with 95% CI. In addition, risk
differences (RD) with 95% CIs were calculated for the primary out-
come and 12-month cumulative live birth. Time to pregnancy leading
to live birth was visualised in a Kaplan–Meier curve. Implantation rate
was defined as the number of gestational sacs visible on ultrasound di-
vided by the number of transferred embryos and was thus calculated
per embryo. In order to account for clustering caused by double
embryo transfers, a Generalised Linear Mixed Model was used.
Analyses were performed using SPSS (IBM SPSS Statistics for




From January 2016 to July 2018, 1065 eligible women were
approached of whom 946 women were randomised. Thirteen women
were excluded for various reasons (Fig. 1) resulting in a total of 933
women included in the ITT analysis: 467 in the scratch and 466 in the
control group (participation rate 88%). Additional information on the
randomisation procedure and stratification per centre can be found in
Supplementary Data File S1, Data File S2 and Table SI.
Baseline and treatment history characteristics are shown in Table I.
In the scratch group, introduction of the biopsy catheter failed in three
participants, and 16 participants did not undergo scratching for other
reasons. In the control group, five women did receive a scratch after
randomisation and before the subsequent IVF/ICSI (Fig. 1). The me-
dian VAS during the scratch procedure was 4.5/10 (interquartile range
3.0–6.0). One week after the scratch procedure, 242/453 women
(53.9%) reported having experienced symptoms of blood loss, abdom-
inal pain and/or fever, but only 12 women (2.6%) reported severe
symptoms and none needed hospitalisation or antibiotic treatment
(Table II).
Follow-up was completed in January 2020 when the last ongoing
pregnancy resulted in live birth. The 12-month study flow is depicted
in Fig. 2. Both groups were comparable as to their exposure to
pregnancy chances in terms of number of started fresh IVF/ICSI cycles
and total number of embryo transfers (Supplementary Table SII).
Additional treatment characteristics of the second IVF/ICSI cycle are
shown in Supplementary Tables SIII and SIV. While the study protocol
demanded no additional scratches during follow-up, in the scratch
group seven women received a second scratch and one woman a sec-
ond and third scratch. In the control group, 11 women received a first
scratch at some point after the second fresh IVF/ICSI treatment but
during follow-up (Supplementary Table SV). Follow-up was completed
for 889 participants (445/467 in scratch and 444/466 in control
group), and 44 of the participants were lost at any time-point after
randomisation.
Outcomes
In women with a previous failed cycle, live birth after the second fresh
IVF/ICSI treatment occurred in 110/465 (23.7%) women in the
scratch and 88/460 (19.1%) in the control group (RR 1.24 [95% CI
0.96–1.59]) (Table III). This equals an RD of 4.6% [95% CI 0.7% to
þ9.9%]. Biochemical pregnancy loss occurred in 17.6% versus 14.6%
(RR 1.21 [95% CI 0.71–2.07]) of the pregnant women in the scratch
and control group, respectively, and miscarriage in 11.1% and 15.3%
(RR 0.73 [95% CI 0.38–1.40]), respectively, of the women with a clini-
cal pregnancy (Table III).
After the full second IVF/ICSI treatment, live birth occurred in
149/465 (32.0%) women in the scratch and 132/460 (28.7%) women
in the control group (RR 1.12 [95% CI 0.92–1.36]). Taking all treat-
ments and pregnancies into account within the 12 months of time hori-
zon, 202/467 (43.3%) women in the scratch and 178/466 (38.2%)
women in the control group had reached a live birth, which corre-
sponds to an RD of 5.1% [95% CI 1.2% to þ11.4%] (Table III). The
course of the 12-month follow-up period, showing time to biochemical
pregnancy leading to live birth, is visualised in Fig. 3.
Results from the AT and ATþET analysis for live birth, biochemical
pregnancy loss and miscarriage were in line with the ITT analysis
(Tables IV and V). Implantation rate was only calculated in the ATþET
analysis. In the scratch group, slightly more embryos were transferred
in the second fresh IVF/ICSI treatment, and relatively more of these




































..embryos implanted: 121/435 (27.8%) embryos in the scratch group
and 99/413 (24.0%) in the control group (RR 1.09 [95% CI 0.96–
1.25]) (Table V).
Discussion
The SCRaTCH multicentre trial included women with one failed
IVF/ICSI treatment. After the fresh IVF/ICSI treatment directly after
randomisation, 4.6% more live births were observed in the endome-
trial scratch group compared to controls, consistent with a true differ-
ence of between 0.7% and þ9.9%. After 12 months of follow-up,
the cumulative live birth rate was 5.1% higher in the scratch group
compared to controls, compatible with a true difference of between
1.2% and þ11.4% with 95% confidence.
Several reviews on endometrial scratching have been published,
with some stating a cautious association between endometrial injury
and increased pregnancy rates whilst others stated that no firm conclu-
sions can be drawn. The overall message was that the studies
performed up to that date included small sample sizes, heterogeneous
study populations and had a high risk of bias (Nastri et al., 2015;
Santamaria et al., 2016; Zygula et al., 2016; Vitagliano et al., 2018;
van Hoogenhuijze et al., 2019). The high risk of bias was also con-
firmed by a recent study that assessed methodological issues in
RCTs on endometrial scratching in IVF/ICSI treatments (Li et al.,
2019): they concluded that almost all of the RCTs (23/25) suffered
from at least one issue regarding trial registration, statistical meth-
ods or reproducibility of baseline/intermediate outcomes, and that
many (19/25) had multiple issues. Fully published studies that had
adequate trial registration and were evaluated as having no or few
issues regarding statistical method or outcome inconsistencies in-
clude the PIP trial (Lensen et al., 2019a), a study by Nastri et al.
(2013) and a trial by Mak et al. (2017). In addition, two RCTs have
been published even more recently: an RCT performed in
Denmark (Olesen et al., 2019) and the REFRESH trial (Mackens
et al., 2020).
Nastri et al. (2013) evaluated endometrial scratching by Pipelle com-
pared to a sham procedure (drying the cervix with a gauze) 7–14 days
Figure 1. Flow chart of study inclusion. IC, informed consent; ITT, intention to treat. aTwo participants provided IC but were accidentally
registered as refuser due to misinterpretation of one of the items on the randomisation form. After discovering the unintended mistake, the
randomisation was still performed. Cases were considered as protocol violations if the outcome was contrary to the misinterpreted allocation, and
were analysed according to the ITT and the as-treated principle. bHardcopy IC was mandatory by the Institutional Review Board. Participants
who were randomised based on a digital copy of the IC and failed to hand over the hardcopy IC (despite repeated attempts to retrieve this) had to
be excluded from analysis.






















































prior to ovarian stimulation in 158 women using oral contraceptives
and undergoing a fresh IVF/ICSI treatment. They found a statistically
significant difference in live birth, with 41.77% live birth in the scratch
group compared to 22.78% in the control group (RR1.83 [95% CI
1.13–2.97]).
Likewise, the Danish multicentre trial observed 6.9% more live
births after mid-luteal phase scratching prior to ovarian stimulation in
304 women with at least one previous failed IVF/ICSI treatment (non-
significant difference) (Olesen et al., 2019). Post-hoc subgroup analyses
did not yield significant results, but non-significant differences in live
birth were observed with increased live birth rates after scratching in
women with one failed transfer (RD 8.9%) and three or more failed
transfers (RD 15.9%), and decreased live birth rate for women with
two failed transfers (RD 11.0%). Mak et al. (2017) also performed
an RCT that evaluated mid-luteal phase Pipelle scratching prior to the
embryo transfer cycle, but they studied this in an unselected popula-
tion undergoing a natural-cycle frozen-thaw embryo transfer, and they
compared it to a control group undergoing an ‘endocervical manipula-
tion’ sham procedure. No significant difference in combined outcome
ongoing pregnancy/live birth rate was found (34.4% in the scratch
group compared to 31.2% in the control group, RR 1.16 [95% CI
0.63–2.14]) (Mak et al., 2017).
The PIP trial was a multicentre RCT including 1364 unselected par-
ticipants undergoing fresh or frozen embryo transfers. Lensen et al.
(2019a) compared a scratch, performed with an endometrial biopsy
catheter anytime between cycle day 3 of the pre-transfer and cycle day
3 of the transfer cycle, to no scratch or sham, and found exactly no dif-
ference with 26.1% live births in both the scratch and control group.
The REFRESH RCT studied endometrial scratching in the follicular
phase of the transfer cycle of 200 women, but stopped prematurely
due to safety concerns. In interim analysis—the trial aimed to include
400 women—a higher miscarriage rate was observed in the scratch
group (25% versus 8% in controls), while the live birth rate was
............................................................................................................................................................................................................................
Table I Baseline characteristics of the participants.
Scratch (n 5 467) Control (n 5 466)
Female age, years 35.5 (31.8–39.0) 35.4 (31.4–38.7)
Female BMI, kg/m2a 23.5 (21.1–26.1) 24.1 (21.5–27.3)
Duration of infertility, months 29.0 (20.0–43.0) 32.0 (20.0–45.0)
Female smokersb 57 (12.6%) 62 (13.6%)
Type of infertility of the femalec
Primary 263 (56.3%) 257 (55.2%)
Secondary 204 (43.7%) 209 (44.9%)
Cause of infertility
Idiopathic 138 (29.6%) 137 (29.4%)
Male factor 225 (48.2%) 213 (45.7%)
Tubal factor 21 (4.5%) 23 (4.9%)
Ovulatory disorder 18 (3.9%) 16 (3.4%)
Endometriosis grade I/II 5 (1.1%) 3 (0.6%)
Other 18 (3.9%) 25 (5.4%)
Mixed diagnosis 42 (9.0%) 49 (10.5%)
No. of previous embryo transfers—per participant 2.3 (§1.6) 2.2 (§1.5)
Data are presented as median (interquartile range), number (%) or mean (§SD).
aData were missing for two participants in the scratch group and eight participants in the control group.
bData were missing for 13 participants in the scratch group and 10 participants in the control group.
cPrimary: female has never conceived before. Secondary: female has conceived before.
......................................................................................................
Table II Symptoms within the first week after the
scratch.
Scratch (n 5 453)












Telephone consultation with hospital 2
Hospital visit and/or antibiotic Trt. 0
Hospitalisation 0
Unknown severity 1
Data were missing for four participants. In total, 112 participants reported experienc-
ing more than one symptom: blood loss and abdominal pain (n¼ 111), blood loss and
fever (n¼ 1). Women in the control group were not contacted to ask for any
symptoms.
Trt, treatment.



























.comparable between scratch and controls (32% versus 36%, respec-
tively) (Mackens et al., 2020).
Like the current trial, all five RCTs mentioned above performed
the scratch using an endometrial biopsy catheter (suction), but all
have significant differences in their study population, scratching
method and subsequent ART treatment. While the trials by
Nastri et al. (2013) (unselected population), Olesen et al. (2019)
(at least one failed IVF/ICSI cycle), and the SCRaTCH trial (just
one failed IVF/ICSI cycle) studied the effect of mid-luteal scratching
before a fresh treatment with ovarian stimulation, the trial by Mak
et al. (2017) did this in a population undergoing natural-cycle fro-
zen-thaw embryo transfer (Nastri et al., 2013; Mak et al., 2017;
Olesen et al., 2019). The REFRESH trial also included only
women undergoing a fresh ovarian stimulation treatment, but
they performed the scratch in the same-cycle follicular phase
(Mackens et al., 2020). The PIP trial included an unselected popu-
lation undergoing either fresh or frozen transfer cycles, but per-
formed the scratch at any time between the cycle days three of the
pre-transfer and same cycle (Lensen et al., 2019a). The three trials
that studied mid-luteal scratching prior to ovarian stimulation ob-
served increased live birth rates in the scratch group, while the
trials evaluating scratching prior to frozen-thaw cycles or other-
timed scratching found no difference in pregnancy rates, or even
a possible harmful effect. These findings together suggest that the
timing of the scratch and/or the specific patient population may
play a role in the outcome.
Figure 2. Flow chart of follow-up period. SET, single embryo transfer; DET, double embryo transfer; OPU, ovum pick-up; ET, embryo trans-
fer. Only treatments are included of which the transfer could have resulted in an ongoing pregnancy (gestational age 10 weeks) at 12 months after
randomisation. aScratch group: one participant was withdrawn by the local investigator because of serious intercurrent disease. Control group: four
participants withdrew consent immediately after randomisation. The other participants were true lost to follow-up. bOther reasons for cancel
OPU: Scratch group: one used wrong stimulation dose, one personal circumstances. Control group: one ovarian cyst, one intercurrent disease, one
premature ovulation, two no spermatozoa, one intracavitary remnants of previous miscarriage, two patient preference. cData on SET or DET
are missing for one participant, but it is known that she had an embryo transfer. dSupplementary Table SII provides cumulative information about the
subsequent IVF/ICSI treatments.




































..The SCRaTCH trial is the only RCT on scratching in the pre-
transfer cycle with a follow-up period that extends beyond one em-
bryo transfer. This enables looking into a possible carry-over effect of
the scratch over multiple transfer cycles. In our results, the difference
in live births was observed directly after the fresh transfer—after that,
the control group did not seem to ‘catch up’ despite having had similar
numbers of embryo transfers during the full study period. It remains
difficult how to interpret these results as there are no RCTs for com-
parison and the putative biological effect of scratching has not been
clarified. If, in the future, endometrial scratching appears to positively
affect live birth chances, the biological and clinical effects in the long
term should be evaluated further.
Important strengths of the SCRaTCH trial are the high participation
rate, which reduces the risk of participation bias and improves general-
isability, and that the study was powered on the outcome ‘live birth’,
which is clinically the most important. The high participation rate most
likely stems from the fact that in the Netherlands, scratching is not
performed outside of clinical trials. Furthermore, the longer follow-up
period allows us to study if a possible carry-over effect of scratching
exists and if a single endometrial scratch leads to a reduced number
of IVF/ICSI treatments needed to achieve a live birth over
12 months of time. This would be beneficial both in terms of patient
burden and healthcare costs. A high rate of completion of follow-up
was achieved in both arms, making the cumulative 12-month out-
come more robust. Another strength is that the scratch was per-
formed according to a strict protocol and using standardised timing,
thereby limiting factors that could affect the possible effect of
scratching. Lastly, the relative homogeneity of the study popula-
tion—all participating women had undergone one previous IVF/ICSI
treatment with at least one embryo transfer—could be interpreted
as both a strength and a limitation: a strength because it reduces
the possible confounders for an effect of scratching, and a limitation
in terms of generalisability to participants with different numbers of
failed IVF/ICSI transfers.
An important limitation is the lack of blinding. As endometrial
scratching is not offered in daily practice in the Netherlands, allocation
to the scratch group could have been an incentive to continue treat-
ment despite, for instance, doubts or a suboptimal response.
............................................................................................................................................................................................................................






2nd fresh IVF/ICSI treatment (i.e. 1st after randomisation)a
Biochemical pregnancy 153 (32.9%) 130 (28.2%) 1.17 0.96–1.42
Clinical pregnancy 126 (27.1%) 111 (24.1%) 1.13 0.90–1.40
Ongoing pregnancy 112 (24.1%) 94 (20.4%) 1.18 0.93–1.51
Live birthb,c 110 (23.7%) 88 (19.1%) 1.24 0.96–1.59
Live birth Risk Difference 4.6% 0.7% to þ9.9%
Biochemical pregnancy lossd 27 (17.6%) 19 (14.6%) 1.21 0.71–2.07
Miscarriagee 14 (11.1%) 17 (15.3%) 0.73 0.38–1.40
2nd full IVF/ICSI treatment (i.e. 1st after randomisation)a
Biochemical pregnancy 207 (44.5%) 187 (40.6%) 1.10 0.95–1.28
Clinical pregnancy 175 (37.6%) 161 (34.9%) 1.08 0.91–1.28
Ongoing pregnancy 152 (32.7%) 139 (30.2%) 1.08 0.90–1.31
Live birthb 149 (32.0%) 132 (28.7%) 1.12 0.92–1.36
Cumulative 12 months follow-upf
Biochemical pregnancy 271 (58.0%) 240 (51.5%) 1.13 1.00–1.27
Clinical pregnancy 234 (50.1%) 211 (45.3%) 1.11 0.97–1.27
Ongoing pregnancy 208 (44.5%) 186 (39.9%) 1.12 0.96–1.30
Live birthb 202 (43.3%) 178 (38.2%) 1.13 0.97–1.32
Live birth Risk Difference 5.1% 1.2% to þ11.4%
Singleton 191 (94.6%) 170 (95.5%)
Twin 11 (5.4%) 8 (4.5%)
Data are presented as number (%).
aData were missing for two in scratch group and five in control group because of loss to follow-up, and one in control group was lost after reaching ongoing pregnancy.
bLoss of ongoing pregnancy occurred in 12 women during 12-month follow-up. Six in scratch: termination of pregnancy (4), intra-uterine foetal death (2). Six in control: termination of
pregnancy (3), intra-uterine foetal death (2), extreme premature birth (1).
cModes of conception: natural conception leading to live birth occurred in six women (three in scratch and three in control). In addition, one participant in the control group had a nat-
ural conception but became lost to follow-up after reaching ongoing pregnancy. Escape IUI leading to live birth occurred in one woman in the control group.
dCalculated using the number of biochemical pregnancies as denominator.
eCalculated using the number of clinical pregnancies as denominator.
fConservative analysis, i.e. data are based on all participants (n¼ 933) and participants who were lost to follow-up (n¼ 44) were regarded as not pregnant/no live birth.
RR, risk ratio.































































































Continuation of the second IVF/ICSI treatment was slightly imbal-
anced: while 453 (96.8%) and 445 (96.5%) women in the scratch and
control group, respectively, started this cycle, 386 (82.7%) had a fresh
embryo transfer in the scratch group compared to 368 (79.0%) in the
control group (Fig. 2). Baseline characteristics or ‘subjective’ reasons
for not reaching embryo transfer did not explain this difference, but it
cannot be excluded that participants with a ‘low response’ in the
scratch group were less inclined to cancel their treatment than partici-
pants in the control group. In this instance, performance bias caused
by resentful demoralisation is imaginable, but a sham procedure may
also cause endometrial disruption, making blinding in scratch research
a difficult choice (Lensen, 2018). In a study by Lensen (2018) on the
use of a sham procedure in scratch research, knowledge of allocation
was not proven to affect participant behaviour. In the current trial, the
as-treated analysis on the population that received an embryo transfer
(ATþET) was performed in order to eliminate the effect of cycle can-
cellation. Importantly, this analysis showed similar results to the ITT
analysis: a higher incidence of live births in the scratch group
(Table V). This suggests that the observed difference in live birth is not
merely a result of less embryo transfers being performed in the con-
trol group. Also, the slight imbalance in embryo transfers was only
seen in the second IVF/ICSI treatment and not for subsequent IVF/
ICSI treatments (Fig. 2). In fact, the total number of started cycles and
embryo transfers during the study period of 12 months did not differ
between the groups (Supplementary Table SII). Lastly, our literature-
based power calculations were based on an expected 9% increase—
from 30% to 39%—in live birth after the second fresh IVF/ICSI treat-
ment. This increase may have been overly optimistic, which now
leaves us with the difficult interpretation of an observed difference in
live birth that to many clinicians and patients may come across as clini-
cally relevant, but that has an uncertainty range also including a small
negative effect. On the other hand, our live birth rates were lower
than the estimated 30% chance of live birth for the control group. As
no Dutch ART statistics were available for our specified population,
we based our estimations on previously published literature on
endometrial scratching and on the pregnancy rates of the general
population undergoing ART in the Netherlands. In hindsight, we think
that the 30% live birth rate was an overestimation of live birth chances
and believe that our observations of 19.1% live birth rate in the con-
trol group reflect the average chance of live birth for our population in
the Netherlands. While this may come across as a limitation, the
lower ‘basal’ live birth rates actually increase the power of the out-
come statistics—therefore, we do not consider this as a limitation of
the trial.
Implications for future research
The first scratching RCTs focused on patients with recurrent implanta-
tion failure (Raziel et al., 2007; Karimzadeh et al., 2009; Shohayeb and
El-Khayat, 2012), but over time scratching studies have shifted towards
patients without a history of (repeated) implantation failure (Liu et al.,
2017; Hilton et al., 2019). Nevertheless, general belief still is that if
scratching works, it would do so for patients that had suffered from
multiple implantation failures (Lensen et al., 2016). The results of the
smaller Danish trial support this theory (Olesen et al., 2019), but this
trend was not observed in the REFRESH or the large PIP trial (Lensen
et al., 2019a; Mackens et al., 2020). Although the possibility exists that
scratching has no or even a slight negative effect, the observed 4.6%
difference in live birth is still an incentive to further assess whether a
true effect exists. For this reason, a marker analysis that evaluates
whether patient characteristics modify the effect of scratching will be
performed on the SCRaTCH dataset to test whether certain sub-
groups of patients might benefit from scratching. Furthermore, the
SCRaTCH, PIP, REFRESH and Danish trials are all part of an individual
Figure 3. Time to biochemical pregnancy leading to live
birth. Intention-to-treat analysis. Kaplan–Meier curve showing the
time to biochemical pregnancy for the scratch (n ¼ 467) and control
(n ¼ 466) groups. Participants who were lost to follow-up (scratch
group n ¼ 22; control group n ¼ 22) were regarded as ‘not
pregnant/no live birth’.
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Second fresh IVF/ICSI treatment (i.e. first after randomisation)a
Biochemical
pregnancy
148 (32.7%) 135 (28.7%) 1.14 0.94–1.39
Clinical
pregnancy
123 (27.2%) 114 (24.2%) 1.12 0.90–1.40
Ongoing
pregnancy
109 (24.1%) 97 (20.6%) 1.17 0.92–1.49
Live birth 107 (23.7%) 91 (19.4%) 1.22 0.95–1.57
Live birth risk difference 4.3% 1.0% to þ9.6%
Biochemical
pregnancy lossb
25 (16.9%) 21 (15.6%) 1.09 0.64–1.85
Miscarriagec 14 (11.4%) 17 (14.9%) 0.76 0.40–1.48
Data are presented as number (%).
aParticipants who were lost before the start of the subsequent treatment (n¼ 7) or
whose scratch was attempted but failed (n¼ 3) were excluded. For live birth, data of
one participant was missing.
bCalculated using the number of biochemical pregnancies as denominator.
cCalculated using the number of clinical pregnancies as denominator.































































































participant data-analysis (IPD) (van Hoogenhuijze et al., 2017a) that
will provide more power to detect a possible effect of scratching in dif-
ferent subgroups.
Implications for clinical practice
Studies conducted thus far have been too small to test whether a
difference of 4–5% is statistically significant, while many clinicians
and patients might find it clinically relevant. One could argue that
scratching is simple, carrying a low risk of serious complications and
could potentially increase live birth rates, which justifies implementa-
tion in daily practice. On the other hand, despite the fact that the
largest proportion of the 95% CI is positive, we should keep in
mind that the possibility exists that endometrial scratching has no,
or even a small negative, effect on live birth rate. Participants expe-
rienced the procedure as mildly painful and a little over half of the
participants reported any kind of complaints during the week after
scratching, although it has to be noted that participants of the con-
trol group were not contacted to ask for symptoms. Thus, we cannot
confirm whether the symptoms reported are related to the scratch or
perhaps are caused by other medication used by the participants, such
as pituitary down-regulation. Furthermore, patients undergoing fertility
treatment are vulnerable (Nap and Evers, 2007) and clinicians should
therefore carefully weigh the risk of withholding possibly effective treat-
ment versus inappropriately offering interventions that increase both
patients’ hopes and expenses. Therefore, implementation of scratching
into daily practice is premature. The IPD will be of major importance in
the decision of whether or not endometrial scratching could become
part of standard care.
Conclusion
In conclusion, in couples with one failed IVF/ICSI treatment, a 4.6%
higher live birth rate after the second fresh IVF/ICSI treatment was
observed after endometrial scratching, with an estimated true effect
between 0.7% and þ9.9%. A difference of 5.1% (95% CI 1.2% to
þ11.4%) was still seen after 12 months, taking all treatments and preg-
nancies within that period into account. These results suggest that a
possible effect of scratching may be smaller than anticipated and/or
may only apply to specific groups of women: addressing this will re-
quire larger sample sizes that will be provided by the currently ongoing
IPD. At present scratching should not be applied outside of clinical
trials.
Supplementary data
Supplementary data are available at Human Reproduction online.
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Table V Pregnancy outcomes—as-treated analysis of the






Second fresh IVF/ICSI treatment (i.e. first after randomisation)
Biochemical
pregnancy
143 (38.5%) 112 (32.7%) 1.18 0.97–1.44
Clinical
pregnancy
119 (32.1%) 96 (28.0%) 1.15 0.92–1.44
Ongoing
pregnancy
106 (28.6%) 81 (23.6%) 1.21 0.94–1.55
Live birth 104 (28.0%) 76 (22.2%) 1.27 0.98–1.64
Live birth risk difference 5.8% 0.5% to þ12.1%
Biochemical
pregnancy lossa
24 (16.8%) 16 (14.3%) 1.18 0.66–2.10
Miscarriageb 13 (10.9%) 15 (15.6%) 0.70 0.35–1.40
Total no. of embryos
transferred
n¼ 435 n¼ 413
Implantation ratec 121 (27.8%) 99 (24.0%) 1.09 0.96–1.25
Data are presented as number (%).
aCalculated using the number of biochemical pregnancies as denominator.
bCalculated using the number of clinical pregnancies as denominator.
cCalculated as the number of gestational sacs divided by the number of embryos
transferred.
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